trial
as of 2026-07-01Metformin for Weight Loss in Schizophrenia
NCTId NCT01177709
at a glance
— · Terminated
Enrollment 12 (actual)
Sponsored by Nathan Kline Institute for Psychiatric Research
Primary completion 2011-04
Synthesized from structured facts only — each point cited above.
Design & status
Phase
—
Status
Terminated
Enrollment
12 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2008-05
Primary completion
2011-04
Eligibility
ALL · 18 Years · 70 Years
Interventions & indications
Sponsors
Nathan Kline Institute for Psychiatric ResearchLead Sponsor
Investigators
1
Robert C. Smith, MD, PhDPrincipal Investigator
Sites
1 total
New York, United States
Facts & assertions
4 sourced
Enrollment
12
Phase
NA
Primary Completion Date
2011-04
Status
TERMINATED
relationships
The graph out of here
drug
drug
lead_sponsor
indication
investigator
person